COVID

1. COVID-19 Diagnostics On March 11, 2020, the World Health Organization declared a global pandemic arising from corona virus disease – 19 (COVID-19). Some of the first cases that began from Wuhan (China) in end of 2019 have reached almost 4,347,935 cases causing 297,241 deaths, worldwide (As of 15 May 2020). On one hand the healthcare systems globally have been struggling to manage the COVID-19 patient population and the researchers are racing to find a solution to this problem; while on the other hand, the economic impacts are felt across other sectors. Globally, there has been GDP decline, increase in unemployment rates, and increase in inflation rates. For instance, in the U.S., by end of April 2020, more than 3.8 million people were laid off and roughly 30 million people filed for jobless aid. In the U.K., around 7.5 million people are covered under furlough scheme, a government’s job retention scheme (May 2012). Top countries to have the most number of confirmed cases (As of 15 May 2020) included the U.S., Spain, Russia, the U.K., Italy, Brazil, France, Germany, Turkey, and Iran. Top countries to have most number of deaths due to COVID-19 (as of 15 May 2020) include the U.S., the U.K., Italy, France, Spain, Brazil, Germany, Iran, Turkey, and India. Key Players Some of the key players involved in the COVID-19 product development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), Takeda Pharmaceuticals Company Ltd (Japan), among others. Scope of the Report: COVID-19 Product Pipeline Diagnosis PCR Testing Antibody Testing Treatment Vaccines Immunotherapy Antiviral Cell-based Therapy Other Therapies

2. COVID-19: Impact on Healthcare Industry Diagnostics Rapid Test Kits PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests Advantages Offered by PCR Testing in COVID -19 Diagnosis Restraints Key Companies Antibody Testing / Serological Testing Advantages Over Molecular Tests Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down Restraints Key Companies Therapies Vaccines Immunotherapies (Antibodies) Monoclonal Antibody T-Cell Therapy Potential Game Changers: Antibodies Ilaris (Canakinumab) Sylvant (Siltuximab) Lenzilumab Ultomiris (Ravulizumab-Cwvz) Tocilizumab Anti-Virals Potential Game Changers Chloroquine and Hydroxychloroquine (HCQ) Remdesivir Cell-Based Therapies Other Therapies Plasma Therapy

3. Devices COVID-19 Industry Impact Assessment, by Geography North America Europe Asia-Pacific (APAC) Rest of the World (RoW) ???????????????????? @ https://www.meticulousresearch.com/download-sample- report/cp_id=5098?utm_source=sb&utm_medium=Social&utm_campaign=Product&utm_content=1 3-12-2022